Looking ahead at 2020, we anticipate a ballot crowded with initiatives, many of which could have a significant impact on California’s life sciences industry. The issues being covered range from consumer privacy, which we have previously discussed at length, to commercial property taxes and funding for California’s stem cell agency.
CLSA recently released the findings of a CLSA-commissioned study, conducted by international health economics firm Vital Transformation, to examine the impact of using international reference pricing in Medicare Part D (as proposed in H.R. 3, the Lower Drug Costs Now Act of 2019) on California’s innovative biotechnology sector.
The enactment of the California Consumer Privacy Act of 2018 (AB 375) (CCPA) brought sweeping restrictions on the collection and use of consumer information. A clean-up bill that same year, SB 1121 (Dodd), added key exceptions to the CCPA to help protect clinical trials and other biomedical research from unintended consequences, including exceptions for, among other things, protected health information (PHI) under federal law and information collected as part of a clinical trial subject to various laws and guidelines.